Each 1-hour session will include 3 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for MM. Each event will employ an identical format that will include the following elements:

• • Discussion of Steering Committee Members’ Treatment Recommendations
• • Review of Available Clinical Research Findings
• • Integration of Interactive Audience Polling Results

MODULE 1 Clinical Decision-Making for Patients with Newly Diagnosed MM MODULE 2 Contemporary Management of Relapsed/Refractory MM MODULE 3 Novel Agents and Strategies in Late-Stage Development

Target Audience
This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of MM.

Learning Objectives

• Discuss available research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into the clinical management of this disease.
• Customize induction, consolidation and maintenance therapeutic approaches for active MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
• Evaluate research data supporting a role for minimal residual disease (MRD) status in predicting long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in protocol and nonresearch management of MM.
• Apply published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory MM.
• Discuss available data documenting the activity of chimeric antigen receptor T-cell therapy and antibody-drug conjugates designed to target BCMA (B-cell maturation antigen), and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches on clinical trials.
• Assess the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel, investigational approaches for MM, and consider the potential role of these therapies in clinical practice.

Physician Competencies To Be Addressed
Patient Care and Procedural Skills, Medical Knowledge.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the conclusion of the activity.

Contact Information
For questions regarding credit, please contact USF Health at cpdsupport@usf.edu or 813-224-7860.

Accreditation Statement
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Privacy Disclosure
Learners provide permission for USF Health to share their completion data with ACCME, who will transmit same on their behalf to ABIM. Within 60 days of the end of the activity, USF Health will upload to ACCME the participant data of physicians who have met the ABIM MOC Points requirements; ACCME will transmit the same to ABIM.

Completion Requirements
Physicians seeking ABIM Points will be required to take an evaluation/post-test passing with a score of 80% or higher.

Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Equal Opportunity Statement
USF Health is an Equal Opportunity/Affirmative Action/Equal Access Institution.

Content Validation and Disclosures
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

STEERING COMMITTEE — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Rafael Fonseca, MD
Getz Family Professor of Cancer
Director for Innovation and Transformational Relationships
Interim Executive Director of the Mayo Clinic Comprehensive Cancer Center
Chair, Department of Internal Medicine
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona

Advisory Committee: Adaptive Biotechnologies Corporation; Consulting Agreements: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Sanofi Genzyme, Takeda Oncology.

Jonathan L Kaufman, MD
Associate Professor of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Tecnofarma; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Fortis Therapeutics, Janssen Biotech Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc.

Shaji K Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Advisory Committee: AbbVie Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Takeda Oncology; Consulting Agreements: AbbVie Inc, Amgen Inc, Celgene Corporation, Cellectar Biosciences Inc, GeneCentrix Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Molecular Partners, Oncopeptides, Takeda Oncology; Contracted Research (to Institution): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio.

Ola Landgren, MD, PhD
Professor of Medicine
Chief, Myeloma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc; Contracted Research: Amgen Inc, Janssen Biotech Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc, Merck, Takeda Oncology, Theradex Oncology.

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

Joseph Mikhael, MD
Professor
Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
City of Hope Cancer Center
Phoenix, Arizona

Consulting Agreements: Amgen Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Takeda Oncology.

Nikhil C Munshi, MD
Kraft Family Chair
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, BeiGene, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep.

Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Consulting Agreement: STATinMED; Contracted Research: BioTheryX Inc, CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals North America Inc; Ownership Interest: Asylia Therapeutics Inc (founder, patents, equity).

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Lilly.

Nina Shah, MD
Associate Professor of Medicine
University of California, San Francisco
Division of Hematology-Oncology
San Francisco, California

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Nektar, Oncopeptides, Precision BioSciences, Sanofi Genzyme, Seattle Genetics, Surface Oncology; Ownership Interest: Indapta Therapeutics; Contracted Research: bluebird bio, Celgene Corporation, Janssen Biotech Inc, Sutro Biopharma, TeneoBio.

CONTRIBUTING ONCOLOGISTS — The following contributors (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Warren S Brenner, MD
Lynn Cancer Institute
Boca Raton, Florida

Speakers Bureau: Celgene Corporation, Takeda Oncology.

Ranju Gupta, MD
Attending Physician
Co-Director, Cardio-Oncology Program
LVPG Hematology Oncology Associates
Lehigh Valley Health Network
Bethlehem, Pennsylvania

Speakers Bureau: Lilly.

Sulfi Ibrahim, MD
Hematology/Oncology
Reid Health
Richmond, Indiana

No financial interests or affiliations to disclose.

Zanetta S Lamar, MD
Florida Cancer Specialists and Research Institute
Naples, Florida

No relevant conflicts of interest to disclose.

Neil Morganstein, MD
Hematology Oncology
Atlantic Health System
Summit, New Jersey

No financial interests or affiliations to disclose.

Shachar Peles, MD
Florida Cancer Specialists and Research Institute
Atlantis, Florida

Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, TG Therapeutics Inc, Verastem Inc; Speakers Bureau: Janssen Biotech Inc, Takeda Oncology.

Erik J Rupard, MD
Chief, Division of Hematology-Oncology
Tower Health – McGlinn Cancer Institute
West Reading, Pennsylvania

No financial interests or affiliations to disclose.

PROJECT CHAIR  — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

USF HEALTH CPD STAFF, RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — No relevant conflicts of interest to disclose.

Commercial Support
These activities are supported by educational grants from Adaptive Biotechnologies Corporation, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.